Comparison between Nebulized Magnesium Sulphate (MgSO₄) Versus Nebulized Salbutamol in Acute Exacerbation of Asthma in Children: A Clinical Trial

Objective: This study aimed to evaluate whether nebulized magnesium sulphate (MgSO₄) offers any clinical advantage over nebulized salbutamol in children presenting with acute asthma exacerbations. Methods: We carried out a six-month randomized controlled trial from September 2024 to March 2025 in the Paediatrics Department at Shaikh Zayed Hospital, Lahore. A total of 100 children between 2 and 12 years of age, all with moderate to severe exacerbations (Paediatric Asthma Severity Score [PASS] > 8), were recruited. Using a double-blind design, they were randomly assigned to receive either nebulized MgSO₄ (Group A, n=50) or nebulized salbutamol (Group B, n=50). Each child was given three nebulizations 20 minutes apart. The primary outcome was defined as a fall of at least 4 points in PASS after 6 hours. Results: The two groups were well matched at baseline, with mean ages of 7.1 ± 2.6 years in the MgSO₄ group and 7.4 ± 2.8 years in the salbutamol group, and a slight male predominance in both (60% and 58%, respectively). After six hours, children receiving MgSO₄ demonstrated a greater improvement: mean PASS dropped by 5.3 ± 1.4 points compared with 4.1 ± 1.6 points in the salbutamol group (p=0.002). A clinically meaningful response (≥4-point reduction) was achieved in 86% of children on MgSO₄ versus 68% on salbutamol (p=0.04). Oxygen saturation also rose more sharply in the MgSO₄ group, from 89.3% ± 3.4 to 96.8% ± 2.1, compared with an increase from 89.6% ± 3.6 to 95.2% ± 2.8 in the salbutamol group (p=0.03). No serious adverse effects were observed, apart from minor throat irritation in a few cases. Conclusion: Nebulized magnesium sulphate proved more effective than salbutamol alone in improving clinical outcomes for children with acute asthma exacerbations. Its ease of administration, safety profile, and low cost support its potential role as an adjunct therapy in routine pediatric emergency care.

Authors

Institutions

Publication Details

Journal
Indus journal of bioscience research.
Published
2025-07-15
DOI
https://doi.org/10.70749/ijbr.v3i7.2361
Primary Topic
Inhalation and Respiratory Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparison between Nebulized Magnesium Sulphate (MgSO₄) Versus Nebulized Salbutamol in Acute Exacerbation of Asthma in Children: A Clinical Trial

Sana Iqbal, Hafsa Nazir, Shagufta Bano, Anus Tariq et al.
Indus journal of bioscience research.
Inhalation and Respiratory Drug Delivery
article

Comparison between Nebulized Magnesium Sulphate (MgSO₄) Versus Nebulized Salbutamol in Acute Exacerbation of Asthma in Children: A Clinical Trial

Sana Iqbal, Hafsa Nazir, Shagufta Bano, Anus Tariq, A. Jamal, Lubna Riaz
article en

Abstract

Objective: This study aimed to evaluate whether nebulized magnesium sulphate (MgSO₄) offers any clinical advantage over nebulized salbutamol in children presenting with acute asthma exacerbations. Methods: We carried out a six-month randomized controlled trial from September 2024 to March 2025 in the Paediatrics Department at Shaikh Zayed Hospital, Lahore. A total of 100 children between 2 and 12 years of age, all with moderate to severe exacerbations (Paediatric Asthma Severity Score [PASS] > 8), were recruited. Using a double-blind design, they were randomly assigned to receive either nebulized MgSO₄ (Group A, n=50) or nebulized salbutamol (Group B, n=50). Each child was given three nebulizations 20 minutes apart. The primary outcome was defined as a fall of at least 4 points in PASS after 6 hours. Results: The two groups were well matched at baseline, with mean ages of 7.1 ± 2.6 years in the MgSO₄ group and 7.4 ± 2.8 years in the salbutamol group, and a slight male predominance in both (60% and 58%, respectively). After six hours, children receiving MgSO₄ demonstrated a greater improvement: mean PASS dropped by 5.3 ± 1.4 points compared with 4.1 ± 1.6 points in the salbutamol group (p=0.002). A clinically meaningful response (≥4-point reduction) was achieved in 86% of children on MgSO₄ versus 68% on salbutamol (p=0.04). Oxygen saturation also rose more sharply in the MgSO₄ group, from 89.3% ± 3.4 to 96.8% ± 2.1, compared with an increase from 89.6% ± 3.6 to 95.2% ± 2.8 in the salbutamol group (p=0.03). No serious adverse effects were observed, apart from minor throat irritation in a few cases. Conclusion: Nebulized magnesium sulphate proved more effective than salbutamol alone in improving clinical outcomes for children with acute asthma exacerbations. Its ease of administration, safety profile, and low cost support its potential role as an adjunct therapy in routine pediatric emergency care.

Indus journal of bioscience research.Vol. 3(7)
Allama Iqbal Medical College (PK), Shaikh Zayed Hospital (PK)
Openalex Percentile: Top 60%
Inhalation and Respiratory Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.